- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02443116
Study of NGM282 in Patients With Nonalcoholic Steatohepatitis (NASH)
September 9, 2020 updated by: NGM Biopharmaceuticals, Inc
A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel-group Multiple-center Study With Additional Open-label Single-blind and Placebo-controlled 24-Week Histology Cohorts to Evaluate the Safety, Tolerability, and Efficacy of NGM282 Administered for Up to 24 Weeks in Patients With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH)
The purpose of this study is to determine the safety, tolerability, and efficacy of NGM282 in patients with nonalcoholic steatohepatitis.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
254
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New South Wales
-
Sydney, New South Wales, Australia
- NGM Clinical Study Site 703
-
-
South Australia
-
Adelaide, South Australia, Australia
- NGM Clinical Study Site 704
-
-
Victoria
-
Melbourne, Victoria, Australia
- NGM Clinical Study Site 701
-
Melbourne, Victoria, Australia
- NGM Clinical Study Site 705
-
-
-
-
-
San Juan, Puerto Rico
- NGM Clinical Study Site 916
-
-
-
-
Arizona
-
Chandler, Arizona, United States
- NGM Clinical Study Site 922
-
Tucson, Arizona, United States
- NGM Clinical Study Site 923
-
-
California
-
Los Angeles, California, United States
- NGM Clinical Study Site 924
-
San Diego, California, United States
- NGM Clinical Study Site 901
-
-
Colorado
-
Denver, Colorado, United States
- NGM Clinical Study Site 902
-
-
Florida
-
Lakewood Ranch, Florida, United States
- NGM Clinical Study Site 917
-
-
Illinois
-
Chicago, Illinois, United States
- NGM Clinical Study Site 906
-
-
Missouri
-
Kansas City, Missouri, United States
- NGM Clinical Study Site 918
-
-
North Carolina
-
Durham, North Carolina, United States
- NGM Clinical Study Site 903
-
-
Tennessee
-
Germantown, Tennessee, United States
- NGM Clinical Study Site 921
-
-
Texas
-
Dallas, Texas, United States
- NGM Clinical Study Site 910
-
Rollingwood, Texas, United States
- NGM Clinical Study Site 920
-
San Antonio, Texas, United States
- NGM Clinical Study Site 905
-
San Antonio, Texas, United States
- NGM Clinical Study Site 909
-
-
Virginia
-
Charlottesville, Virginia, United States
- NGM Clinical Study Site 904
-
Richmond, Virginia, United States
- NGM Clinical Study Site 911
-
-
Washington
-
Seattle, Washington, United States
- NGM Clinical Study Site 908
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Males or females, between 18 and 75 years of age, inclusive
- Histologically confirmed NASH diagnosis
Exclusion Criteria:
- Clinically significant acute or chronic liver disease
- Prior liver transplantation
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: TRIPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Cohort 1 - Placebo
|
|
Experimental: Cohort 1 - NGM282 3mg
|
|
Experimental: Cohort 1 - NGM282 6mg
|
|
Experimental: Cohort 2 - NGM282 0.3mg
|
|
Placebo Comparator: Cohort 2 - NGM282 1mg
|
|
Experimental: Cohort 2 - NGM282 3mg
|
|
Experimental: Cohort 3 - NGM282 1mg
|
|
Placebo Comparator: Cohort 4 - Placebo
|
|
Experimental: Cohort 4 - NGM282 1mg
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in absolute liver fat content as measured by MRI from Baseline to Week 24
Time Frame: 24 weeks
|
24 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in percentage liver fat content as measure by MRI from Baseline to Week 24
Time Frame: 24 weeks
|
24 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Sanyal AJ, Ling L, Beuers U, DePaoli AM, Lieu HD, Harrison SA, Hirschfield GM. Potent suppression of hydrophobic bile acids by aldafermin, an FGF19 analogue, across metabolic and cholestatic liver diseases. JHEP Rep. 2021 Feb 19;3(3):100255. doi: 10.1016/j.jhepr.2021.100255. eCollection 2021 Jun.
- Loomba R, Ling L, Dinh DM, DePaoli AM, Lieu HD, Harrison SA, Sanyal AJ. The Commensal Microbe Veillonella as a Marker for Response to an FGF19 Analog in NASH. Hepatology. 2021 Jan;73(1):126-143. doi: 10.1002/hep.31523. Epub 2020 Dec 11.
- Harrison SA, Neff G, Guy CD, Bashir MR, Paredes AH, Frias JP, Younes Z, Trotter JF, Gunn NT, Moussa SE, Kohli A, Nelson K, Gottwald M, Chang WCG, Yan AZ, DePaoli AM, Ling L, Lieu HD. Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis. Gastroenterology. 2021 Jan;160(1):219-231.e1. doi: 10.1053/j.gastro.2020.08.004. Epub 2020 Aug 8.
- Harrison SA, Rinella ME, Abdelmalek MF, Trotter JF, Paredes AH, Arnold HL, Kugelmas M, Bashir MR, Jaros MJ, Ling L, Rossi SJ, DePaoli AM, Loomba R. NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2018 Mar 24;391(10126):1174-1185. doi: 10.1016/S0140-6736(18)30474-4. Epub 2018 Mar 5. Erratum In: Lancet. 2018 Mar 24;391(10126):e16.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 31, 2015
Primary Completion (Actual)
December 6, 2019
Study Completion (Actual)
January 17, 2020
Study Registration Dates
First Submitted
May 11, 2015
First Submitted That Met QC Criteria
May 12, 2015
First Posted (Estimate)
May 13, 2015
Study Record Updates
Last Update Posted (Actual)
September 11, 2020
Last Update Submitted That Met QC Criteria
September 9, 2020
Last Verified
September 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 15-0105
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Nonalcoholic Steatohepatitis (NASH)
-
Milton S. Hershey Medical CenterNot yet recruitingLiver Diseases | NASH - Nonalcoholic Steatohepatitis | NASH
-
Milton S. Hershey Medical CenterRecruitingExercise | NASH - Nonalcoholic Steatohepatitis | NASH | LiverUnited States
-
Polaris GroupRecruiting
-
Corcept TherapeuticsRecruitingNonalcoholic Steatohepatitis (NASH)United States
-
PerspectumRecruitingNASH - Nonalcoholic SteatohepatitisUnited States
-
Metacrine, Inc.Completed
-
Cascade Pharmaceuticals, IncLaboratory Corporation of AmericaCompletedNonalcoholic Steatohepatitis (NASH)United States
-
Poxel SACompletedNASH - Nonalcoholic SteatohepatitisUnited States
-
RWTH Aachen UniversityCompletedNASH - Nonalcoholic SteatohepatitisSweden, Austria, Germany
-
CymaBay Therapeutics, Inc.TerminatedNASH - Nonalcoholic SteatohepatitisUnited States
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States